[Orexin: clinical and therapeutic implications].
INTRODUCTION. Recent research has reported the existence of a new class of neuropeptides, called orexins or hypocretins, which are produced by a small group of neurons in the hypothalamus and whose actions are mediated by two types of receptors: OX1R and OX2R. More specifically, the orexinergic neurons have been located exclusively in cells in the lateral, dorsomedial and perifornical areas of the hypothalamus. Despite this highly specific anatomical origin, the orexinergic neurons are projected widely into a number of brainstem, cortical and limbic regions. DEVELOPMENT. This fuzzy pattern of distribution of the orexinergic fibres would be indicating the involvement of this peptidic system in a wide range of functions; indeed, it has been related with the mechanisms that enable regulation of the sleep-wake cycle, the ingestion of food and drink, and some particular types of learning, such as learning certain preferences regarding tastes. It has also been suggested that upsets in the functioning of the orexinergic system would explain the appearance of certain clinical disorders like narcolepsy, obesity or addiction to drug of abuse. CONCLUSIONS. Further research will help to determine the functioning of orexinergic neurons and the interaction between the systems that regulate emotion, energetic homeostasis and the reward mechanisms, on the one hand, and the systems that regulate the sleep-wake cycle on the other. That knowledge would almost certainly make it possible to develop new drugs that, by acting upon the orexinergic system, would be effective in the treatment of sleep disorders such as insomnia or narcolepsy, eating disorders or drug addiction.
Universidad de Granada, Granada, Espana.
Cristina
C
Mediavilla
Severiano
S
Risco
D000818:Animals; D001143:Arousal / Q000187:drug effects / Q000502:physiology; D001381:Azepines / Q000494:pharmacology / Q000627:therapeutic use; D001583:Benzoxazoles / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005247:Feeding Behavior / Q000502:physiology; D001068:Feeding and Eating Disorders / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics / Q000502:physiology* / Q000627:therapeutic use; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009287:Naphthyridines; D009290:Narcolepsy / Q000188:drug therapy / Q000503:physiopathology; D009479:Neuropeptides / Q000235:genetics / Q000502:physiology* / Q000627:therapeutic use; D009765:Obesity / Q000503:physiopathology / Q000517:prevention & control; D000068796:Orexin Receptor Antagonists; D064446:Orexin Receptors / Q000235:genetics / Q000502:physiology; D000068797:Orexins; D020178:Sleep Disorders, Circadian Rhythm / Q000188:drug therapy / Q000503:physiopathology; D020919:Sleep Disorders, Intrinsic / Q000188:drug therapy / Q000503:physiopathology*; D019966:Substance-Related Disorders / Q000188:drug therapy / Q000503:physiopathology*; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
C420062:1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea; D001381:Azepines; D001583:Benzoxazoles; D047908:Intracellular Signaling Peptides and Proteins; D009287:Naphthyridines; D009479:Neuropeptides; D000068796:Orexin Receptor Antagonists; D064446:Orexin Receptors; D000068797:Orexins; D014230:Triazoles; C551624:suvorexant; D014508:Urea